Seeking Alpha

Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Clinical-Stage Pipeline

-First participant dosed in Phase 1/2 PROSPER trial of FMC-376 in KRAS G12C Cancers - FMC-376 is a first-in-class direct dual inhibitor of ON+OFF KRAS G12C - FMC-376 has the potential to transform ...
Business Insider

Frontier Medicines Announces Publication in Nature Communications Highlighting a Novel Method that Enables Next-Generation Covalent Medicines

BOSTON and SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a clinical-stage precision medicines company unlocking the proteome to develop small molecule ...
Business Insider

Frontier Medicines Announces Third Precision Oncology Development Candidate

- FMC-242 is a potentially best-in-class covalent allosteric inhibitor that breaks the interaction between PI3Kα and RAS, targeting the largest genetic drivers of cancer - - Potential as a monotherapy ...
Yahoo Finance

Frontier Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference

BOSTON and SOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a clinical-stage precision medicines company unlocking the proteome to develop small molecule ...
FOX31 Denver

Frontier Medicines Announces Advancement of Second and Third Programs Under Global Partnership with AbbVie

SOUTH SAN FRANCISCO, Calif. and BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance breakthroughs against ...
WKRG

Frontier Medicines Announces Milestone Payment in AbbVie Partnership, Following Advancement of Lead Candidates Targeting a Historically Undruggable Transcription Factor

BOSTON and SOUTH SAN FRANCISCO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation (“Frontier” or the “Company”), a clinical-stage precision medicine company seeking to unlock ...